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Around 45% of East Asians are unable to fully metabolize ethanol due to functional 
polymorphisms of alcohol metabolism genes, specifically alcohol dehydrogenase (ADH) 
and aldehyde dehydrogenase (ALDH). These individuals display high levels of toxic 
blood acetaldehyde when consuming alcohol, causing symptoms such as tachycardia, 
vomiting, and flushing. The studies included in this review examine how functional 
polymorphisms of ADH and ALDH protect against alcoholism in addition to how 
polymorphisms can be utilized as protection against alcoholism via gene therapy. The 
studies included found that carriers of the ADH and ALDH polymorphisms were 66 to 
99% genetically protected against alcoholism. Through the use of gene pharmacology 
involving ADH and ALDH mimicry, gene therapy was seen to reduce ethanol intake in 
several animal models, furthering the development of new treatments for alcoholism. 
Keywords: aldehyde dehydrogenase, alcohol dehydrogenase, Asian, flush, 





Functional Polymorphisms of Alcohol Metabolism Genes and their Protection Against 
Alcoholism via Gene Therapy: A Systematic Review 
INTRODUCTION 
Many individuals around the world consume alcohol in safe levels. However, a 
significant number of individuals dangerously increase their alcohol intake in a way that 
is susceptible to addiction and alcohol use disorder (AUD) (Enoch, 2014). AUD is a type 
of substance use disorder (SUD) and is a moderately heritable chronic medical illness 
that is very common, affecting an estimated 15 million people in the United States 
(National Institute on Alcohol Abuse and Alcoholism, 2015). SUDs “are characterized by 
clinically significant impairments in health, social function, and impaired control over 
substance use and are precisely diagnosed through assessing cognitive, behavioral, and 
psychological symptoms” (U.S. Department of Health and Human Services, 2016, pg. 6). 
According to the Substance Abuse and Mental Health Services Administration (2017), 
20.1 million people (6.2% of the US population) met the diagnostic criteria for SUD in 
2016, but only 3.8 million individuals (18.9% of those with SUD) received any type of 
treatment. In the case of SUD related to alcohol use, Hasin, Stinson, Ogburn, and Grant 
(2007) noted that the lifetime prevalence of AUD in the United States is 30% and has 
continued to rise each year. 
When an individual becomes addicted to alcohol use, they experience the most 
severe form of AUD. Addiction in the context of AUD is associated with compulsive and 
uncontrolled use of alcohol (U. S. Department of Health and Human Services, 2016). The 
process of developing an addiction to alcohol involves a number of functional genetic 




(2005), the heritability of alcoholism is about 50%. However, only two genes have been 
verified as “addiction genes” in the human body within the context of alcoholism: 
mitochondrial aldehyde dehydrogenase (ALDH) and alcohol dehydrogenase (ADH) 
(Goldman et al., 2005; Higuchi, Matsushita, Murayama, Takagi, & Hayashida, 1995; 
Luczak, Glatt, & Wall, 2006). Both genes are polymorphic in humans, meaning that more 
than one allele can occupy each gene’s locus along a chromosome within a population of 
humans. For example, two forms of ALDH2 exist: ALDH2*2 and ALDH2*1. ALDH2*2 
encodes the inactive form of the ALDH2 enzyme while ALDH2*1 encodes the active, 
more frequent form of the ALDH2 enzyme. The difference in alleles located at each 
gene’s locus results from changes in single nucleotides, which alter the activity of each 
enzyme (Pautassi, Camarini, Quadros, Miczek, & Israel, 2010). This is known as a 
single-nucleotide polymorphism (SNP) (C. Chen, Lu, Y. Chen, Wang, Chang, Li, & Yin, 
1999). Because polymorphisms of each gene can alter the gene’s final functioning 
capacity, all genetic variants of ALDH and ADH are both referred to as functional 
polymorphisms.    
The body’s way of metabolizing alcohol typically includes breaking down ethanol 
within the liver via the ADH enzyme into acetaldehyde while then utilizing the ALDH 
enzyme to further metabolize acetaldehyde into nontoxic acetate (Enoch, 2014; Rivera-
Meza, Quintanilla, Tampier, Mura, Sapag, & Israel, 2010). Those who have a 
polymorphism in the ADH and ALDH enzymes are unable to properly metabolize 
alcohol, leading to the accumulation of acetaldehyde, which is mutagenic and 
carcinogenic to the body. Because the body is unable to fully metabolize ethanol, the 




symptoms of flushing, hypotension, nausea, headache, vomiting, and tachycardia, 
ultimately discouraging further alcohol intake (Chen et al., 1999; Goldman et al., 2005; 
Pautassi et al., 2010). This response to alcohol consumption is known as the flushing 
response, Asian glow, and Asian flush (Higuchi et al., 1995). Individuals who possess 
functional polymorphic alleles of ADH and ALDH are said to have a genetic protection 
against alcohol abuse and alcoholism. In fact, individuals who are heterozygous 
ALDH2*2/ALDH2*1 carriers are protected against alcohol abuse and alcoholism by 66 
to 75% while homozygous ALDH2*2/ALDH2*2 carriers are nearly 100% protected 
(Ocaranza, Quintanilla, Tampier, Karahanian, Sapag, & Israel, 2008). According to 
Enoch (2014), approximately 45% of East Asians (Japanese, Chinese, Koreans, Thais) 
are carriers of the ALDH2*2 allele. More specifically, approximately 31% of Chinese, 
45% of Japanese, 29% of Koreans, and 10% of Thais carry at least one of the variant 
ALDH2*2 allele (Luczak et al., 2006). However, the same allele is rare in Western and 
Central European Whites; although it remains moderately prevalent in Russian and 
Jewish Whites.  
 To understand the interaction between functional polymorphisms of the alcohol 
metabolism genes and their protection against alcoholism, it is important to first 
understand the variations and roles of the major enzymes of alcohol metabolism, ADH 
and ALDH. Four genes are responsible for coding the four forms of ADH that are 
involved in alcohol metabolism (Chen et al., 1999). The four forms of ADH can be split 
between class I (ADH1-3) and class II (ADH4) enzymes. At the ADH2 locus, three 
allelic variants are possible: ADH2*1, ADH2*2, and ADH2*3; at the ADH3 locus, two 




for ADH can dramatically impact the enzyme’s rate of activity within the cell. The same 
is true of the allelic variants of the two forms of ALDH: cytosolic ALDH1 and 
mitochondrial ALDH2. The ALDH2 locus contains two allelic variations: ALDH2*1 and 
ALDH2*2. 
According to Chen et al. (1999), the alleles ADH2*2 and ADH3*1 code for 
different forms of the high-activity ADH enzyme along with the ALDH2*2 allele that 
codes for the low-activity form of ALDH2. The frequency of these three allelic variants 
have been documented to be significantly low in alcoholics when compared to a general 
population of East Asians. Chen and colleagues (1999) tested the hypothesis that the 
allelic variants ADH2*2, ADH3*1, and ALDH2*2 provided substantial protection 
against alcoholism through either faster production or slower removal of acetaldehyde 
among 885 alcoholics and controls of Han Chinese descent in Taiwan. ADH2 and ADH3 
haplotype frequencies were combined with ALDH2 genotypes and then compared 
between the participants diagnosed with alcohol dependence (alcoholic group, n = 340; 
315 males and 25 females; mean age = 40) and a control group (n = 545; mean age = 20) 
comprised of male medical, dental, and pharmacy students that were either nondrinkers 
or occasional light drinkers. Genomic DNA was extracted from subjects’ leukocytes and 
then labeled via polymerase chain reactions (PCR) by their SNP sites to determine each 
subject’s differences in genotypes and alleles associated with alcohol metabolism.  
Chen et al. (1999) found that genotype and allele distributions of the alcohol 
metabolism genes were not significantly different among the Han Chinese alcoholics 
group; however, the genotype and allele distributions of the control group varied 




ADH3, and ALDH2 in predisposition to alcoholism within three tested models 
(codominance model, complete-dominance model, and partial-dominance model), they 
found that the ADH3 locus failed to show a significant effect (p = .23-56) on risk for 
alcoholism. Any previous reports of ADH3 having a significant protection against 
alcoholism was attributed to linkage disequilibrium of the ADH2 and ADH3 alleles (p 
< .013) based on the findings by Chen et al. (1999). The researchers, however, did find 
that the ADH2*1/*2 and ADH2*2/*2 genotypes showed highly significant protection 
against alcoholism (odds ratios [ORs], .12-.19) when compared to the ADH2*1/*1 
genotype. When examining the combined effects of ADH2 and ALDH2, they found that 
ADH2*2/*2-ALDH2*1/*2 carriers have a 20 - 25-fold less risk for alcoholism than 
ADH2*1/*1-ALDH2*1/1 carriers. Most significantly, Chen et al. (1999) found that 
ALDH2*2/*2 homozygosity appeared to completely protect against the development of 
alcoholism while ALDH2*2/*1 heterozygosity displayed partial protection. 
Chen and colleagues’ (1999) study was one of the first studies to incorporate such 
a large number of subjects, assuring that their results could reflect valid population 
statistics among Han Chinese in Taiwan. This study was also one of the first studies that 
comprehensively tested the interactions between ADH2*2, ADH3*1, and ALDH2*2. 
Similar results have been duplicated in several related studies since then, showing that 
ALDH2*2/*2 homozygosity completely protects while ADH2*2/*2 homozygosity 
partially protects (~50%) against the development of alcoholism (Chambers, Marshall, 
Robinson, Maguire, Newton-Howes, & Chong, 2002; Garver, Tu, Cao, Aini, Zhou, & 
Israel, 2001; Kim et al., 2008; Thomasson et al., 1991).  




While several studies have focused on the association between genetic influences 
and their role in determining alcohol consumption patterns among individuals, relatively 
few studies have considered the relationship between functional genetic polymorphisms 
and their ability to be used as a therapy for alcoholism via gene therapy. This systematic 
review paper focuses on studies that examine the functional polymorphisms of two liver 
enzymes (ADH and ALDH) and their ability to be used as a genetic foundation for the 
development of a potential, long-term treatment for alcoholism. In reviewing current 
research concerning the characteristics of ADH and ALDH, this paper considers how 
functional polymorphisms of the alcohol metabolism genes can be utilized as a protection 
against alcoholism and how the use of gene therapy can further the current treatment 
options for alcoholism. 
METHOD 
This systematic review was conducted using the procedures based on the 
Cochrane Group guidelines for systematic reviews (van Tulder, Furlan, Bombardier, 
Bouter, & the Editorial Board of the Cochrane Collaboration Back Review Group, 2003). 
A flow diagram of the search is displayed in Figure 1. Search terms were developed and 
integrated using Boolean logic to find studies targeting the specified population (e.g., 
adolescents, adults, humans, animals), intervention (e.g., gene therapy, adenovirus vector, 
RNA, antisense gene), and outcome measurement (e.g., alcoholism, alcohol behaviors, 
alcohol symptoms, alcohol use, ethanol intake). This systematic search was conducted 
through electronic database searches to identify meeting all inclusion criteria as of March 





   
Figure 1. Flow diagram of article search 
RESULTS 
Table 1 summarizes study methods and results for the five studies that met all 
inclusion criteria. All studies included rats or rat cell lines; no studies included human 
participants. Four studies incorporated versions of adenoviral vectors to alter rat genomes 




adenoviral vector studies, two examined the impact adenoviral vectors would have on 
ALDH activity on rats in vivo and in vitro, one examined the impact adenoviral vectors 
would have on ADH activity in vivo, and one examined the impact adenoviral vectors 
would have on both ADH and ALDH in vivo. The adenoviral vector studies included the 
use of Aldh2 antisense vectors (AdV-AS) (n = 2), both AdV-rADH-47His and AdV-
rADH-47Arg vectors (n = 1), and AdV-ADH/asALDH2 vectors (n = 1) to test respective 
activity levels of ALDH2, ADH, and ADH/ALDH2 after the consumption of ethanol. 
The oligonucleotide study included in this systematic review examined the impact 
antisense phosphorothioate oligonucleotide (ASO) would have on ALDH activity in vivo.  
All five studies found that respective enzyme activity was reduced after the 
introduction of either adenoviral vectors or oligonucleotides (Garver et al., 2001; 
Karahanian, Ocaranza, & Israel, 2005; Ocaranza et al., 2008; Rivera-Meza et al., 2010; 
Rivera-Meza, Quintanilla, & Tampier, 2012). Furthermore, all five studies showed 
increased acetaldehyde levels within infected cells after undergoing gene therapy. This 
reveals that gene therapy within the context of alcohol metabolism is able to mimic the 




Table 1. Study Methods and Results 
 
Article Conditions Type Ethanol 
Dose 
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day 5 (1 g/kg); 
killed after 60 
min  
Rats treated for 3 









• ASO-9 led to 38-45% 
reduction in ALDH2 activity 
and four-fold increase in 
acetaldehyde levels compared 
to control oligonucleotide 
• After 1 h of ethanol 
consumption, ASO-9 groups 
displayed 61% reduction in 
ethanol consumption (p < 
0.015) compared to control 
• After 5 h of ethanol 
consumption, ASO-9 groups 
displayed 45% reduction in 
ethanol consumption (p < 
















































30 100 mm 
dishes of rat 
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ethanol for 1 h 
ALDH2 activity and 
Acetaldehyde 
levels determined 
using a series of 
chemical reactions 
• 48 h after transduction of 
Aldh2 antisense gene led to 
reduction in ALDH2 activity 
(60-70%; p < 0.001) 
• Aldh2 antisense gene led to 
eight-fold increase in 


















2 months 60 d voluntary 
access to 10% 
ethanol; ethanol 
Voluntary water and 
ethanol intake 
recorded; ALDH 
• AdV-AS treated animals 
consumed 50% less ethanol 





















paradigm: access to 
ethanol and water 
for 1 h each day for 




activity and mRNA 
expression 
determined 
to AdV-C treated animals (p < 
0.001) 
• Liver ALDH activity of AdV-
AS treated animals was 85% 
reduced compared to AdV-C 




















































to ethanol and 
water for 1 h each 
day for 13 days 




determined on day 
21 using gas 
chromatography 
• AdV-rADH-47His vector 
showed lower voluntary 
ethanol intake (50% reduction; 
p < 0.001) than animal with 
AdV-noncoding vector 
• AdV-rADH-47Arg vector 
showed lower voluntary 
ethanol intake (30% reduction; 
p < 0.01) than animals with 
AdV-noncoding vector 
• ADH activity in animals with 
AdV-rADH-47His vector (90%; 
p < 0.01) and AdV-rADH-
47Arg vector (32%; p < 0.01) 






































paradigm: Access to 
ethanol and water 
for 1 h each day for 
15 days before 
adenoviral vector 
injection; Access to 
ethanol and water 
for 1 h each day for 








determined using gas 
chromatography; 
ADH and ALDH2 
levels determined 
• AdV-ADH/asALDH2 vector 
showed reduced voluntary 
ethanol intake for 3 weeks 
(60%; p < 0.001) compared to 
AdV-C vector animals 
• AdV-ADH/asALDH2 vector 
showed increased levels of 
blood acetaldehyde with peak 
at 5-10 min after ethanol 
administration (400%; p 
<0.001) compared to AdV-C 
vector animals 
• AdV-ADH/asALDH2 vector 
showed increased activity of 
ADH (176%; p <0.001) 
compared to AdV-C vector 
animals 
• AdV-ADH/asALDH2 vector 
showed decreased activity of 
liver ALDH2 (24%; p <0.01) 




To determine ALDH2 activity in the Karahanian et al. (2005) study, total RNA was 
extracted from hepatoma cells. Antisense RNA was separated from endogenous RNA via reverse 
transcriptase (RT) reactions followed by PCR. ALDH2 activity was then measured. According to 
Karahanian et al. (2005), high levels of both antisense mRNA and sense mRNA was found in 
cells infected with the adenoviral vector carrying the antisense gene; however, antisense mRNA 
did not increase at higher multiplicities of infection (MOIs) of the viral vector. Furthermore, 
ALDH2 activity was reduced 60-70% (p < 0.001) forty-eight hours after transduction of the 
Aldh2 antisense gene while acetaldehyde levels in cells infected with the antisense coding gene 
increased eight-fold (p < 0.001). Although ALDH2 activity showed slight differences at varying 
MOIs, acetaldehyde levels remained the same between the two MOI conditions. Karahanian and 
colleagues (2005) hypothesized that ALDH may begin removing acetaldehyde at high levels due 
to its higher 𝐾𝑚 value, preventing further accumulation of acetaldehyde at a higher MOI. 
Overall, Karahanian et al. (2005) showed the administration of an adenoviral vector carrying an 
Aldh2 antisense gene is able to increase the levels of acetaldehyde in rat cells metabolizing 
ethanol, successfully mimicking the effects of the functional polymorphism ALDH2*2 in 
humans metabolizing ethanol. 
In a following study, Ocaranza and colleagues (2008) used rats bred as high alcohol 
drinkers as their subjects. Over the course of 2 months during which the rats were offered 
voluntary consumption of ethanol (10%) and water, all rats became alcohol dependent. 
Following this 2-month period, one group of rats (n = 4) had the therapeutic AdV administered 
via the tail vein while another group (n = 4) had a control AdV administered. All rats were then 
subjected to a 3-day withdrawal period during which they had no access to ethanol. After the 




only one hour a day) and water (all day) for the following 34 days. Consumption patterns were 
recorded for all rats. Thirty-five days after the withdrawal period, the rats were euthanized and 
their liver ALDH2 activity was determined. 
Ocaranza et al. (2008) observed that both groups of rats consumed intoxicating amounts 
of alcohol on the first day of ethanol re-access after the withdrawal period. However, over the 
next 34 days, the rats who had been administered the therapeutic AdV (AdV-AS) showed a 
dramatic reduction (50% lower than control AdV; p = 0.001) in ethanol intake while the rats 
who had been administered the control AdV (AdV-C) continued to consume ethanol at a high 
rate. The reduction in ethanol consumption was evident five days after the AdV-AS was injected 
and stabilized after 12 - 13 days. When analyzing liver ALDH2 activity, the researchers found 
that liver activity was reduced by 85% in rats that had received AdV-AS in comparison to the 
liver activity of those that had received AdV-C. Most importantly, this study found that gene 
therapy that mimics the low ALDH2 phenotype can elicit deterrence to high alcohol drinking 
even after high alcohol drinking has been established. The study done by Ocaranza and 
colleagues (2008) successfully showed that the single administration of the AdV carrying an 
anti-ALDH2 antisense gene was not only able to reduce liver ALDH2 activity, but it was also 
able to reduce alcohol intake for 34 days, which was the longest period of time studied up until 
that point. This study shows that gene therapy can be used as a possible long-term treatment 
option for alcohol-dependent animals and may be further developed into a long-term treatment 
option for humans with alcoholism. 
To further investigate the mechanism by which alcohol metabolism polymorphisms 
protect against heavy alcohol intake, Rivera-Meza et al. (2010 & 2012) studied alcohol intake in 




the human ALDH2*2 gene in combination with the ADH2*2 gene. In the 2010 study, Rivera-
Meza and colleagues cloned rat wild-type ADH (47Arg) and mutant ADH (47His) using 
methods similar to Karahanian et al. (2005) and Ocaranza et al. (2008) with the exception of 
using different promoter sequences and plasmids. Following this, adenoviral vectors AdV-
rADH-47His and AdV-rADH-47Arg were formed, purified, and intravenously injected into each 
rat depending on which condition they were assigned (n = 6/condition). The rats were then 
allowed access to a 10% ethanol solution and water for 1 hour each day for 13 days before being 
euthanized to determine arterial acetaldehyde levels. According to Rivera-Meza et al. (2010), 
liver ADH activity within animals transfected with AdV-rADH-47His was six times higher than 
that within animals transfected with AdV-rADH-47Arg and 90% higher than that within animals 
transfected with the control AdV (p < 0.01). Additionally, animals that received the AdV-rADH-
47His vector showed a significantly lower voluntary ethanol consumption level (50% reduction; 
p <0.001) than animals that received the control AdV. Overall, ADH2*2 showed that high levels 
of blood acetaldehyde occur only during the first few minutes of ethanol metabolism, resulting in 
a “burst” of acetaldehyde, which causes the reduction in voluntary ethanol intake. This “burst” is 
primarily caused by AdV-rADH-47His having a higher 𝐾𝑚 for NAD+ at its active site and a 6-
fold higher 𝑉𝑚𝑎𝑥 than AdV-rADH-47Arg. 
 In order to expand upon their previous research, Rivera-Meza et al. (2012) developed a 
new therapeutic strategy to treat alcoholism by increasing ADH activity while also reducing 
ALDH2 activity to produce higher blood levels of acetaldehyde during ethanol metabolism. By 
doing so, the expression of both protective genes could be provided within a single adenoviral 
vector. In this study, Rivera-Meza and colleagues (2012) developed a multiple expression 




antisense RNA against rat ALDH2. The adenoviral vector was formed using similar methods to 
that of which was previously described in the 2010 study. The rats in this study were allowed 
access to a 10% ethanol solution and water for 1 hour each day for 15 days before being 
intravenously injected with AdV-ADH/asALDH2. Seventy-two hours after the injection, rats 
were allowed access to ethanol and water for 1 hour each day for 23 days as researchers 
observed their ethanol intake. After the trial period, rats were subjected to seven days of 
abstinence from ethanol intake. After the abstinence period, the rats were given another dose of 
ethanol (1 g/kg) before being euthanized to measure acetaldehyde levels throughout the body.  
Rivera-Meza et al. (2012) found that AdV-ADH/asALDH2 infected animals showed 
increased activity of ADH (176%; p <0.001) and decreased activity of liver ALDH2 (24%; p 
<0.01) compared to AdV-C vector animals. Likewise, AdV-ADH/asALDH2 vector showed 
reduced voluntary ethanol intake for 3 weeks (60%; p < 0.001) compared to AdV-C vector 
animals due to increased levels of blood acetaldehyde that peaked at 5-10 min after ethanol 
administration (400% increased; p <0.001). Overall, this study showed that the paired increase of 
ADH activity and reduction of ALDH2 activity in the liver of alcohol-dependent rats is an 
effective method to reduce the voluntary ethanol intake in rodents, providing evidence of new 
therapeutic strategies for the treatment of alcoholism. 
 In a study by Garver et al. (2001), manufactured antisense phosphorothioate 
oligonucleotides (ASO), specifically ASO-9, was purchased and intravenously administered via 
a femoral venous catheter (15 mg ASO-9/kg/day) in rats for four days. On day five, an oral 
ethanol was administered (1 g/kg) and then the rats were euthanized one hour later in order to 
determine acetaldehyde levels and ALDH activity. Rats receiving the ASO-9 treatment showed a 




activity was reduced by 38-45% and displayed a four-fold increase in acetaldehyde levels after 
ethanol administration under ASO-9 treatment conditions in comparison to the rats in the control 
treatment.  
 To determine if ASO-9 could result in an aversion to ethanol and reduced ethanol 
consumption, Garver et al. (2001) surgically implanted rats with osmotic pumps which delivered 
ASO-9 at 24 mg/kg/day intraperitoneally. Three days after implantation with no access to water 
on the last night, rats were offered 6% ethanol as the only fluid and consumption was observed 
and measured at five hour intervals.  During the first hour of ethanol presentation, initial ethanol 
consumption was similar in both the ASO-9 and control groups, resulting in 1.12 ± 0.9 g 
ethanol/kg (ASO-9) and 1.70 ± 0.68 g ethanol/kg (control). After the first hour, consumption was 
reduced significantly (p < 0.015) in the ASO-9 group (0.48 ± 0.23 g ethanol/kg) compared with 
the control group (1.22 ± 0.116 g ethanol/kg). Overall, a 45% reduction in ethanol consumption 
in ASO-9 treated animals was measured in comparison to animals receiving the control treatment 
(p <0.035). 
 All five studies included in this systematic review were able to utilize gene therapy 
techniques to mimic the functional polymorphisms of alcohol metabolism genes found primarily 
in East Asians within rat studies. As a result, all of the studies were able to lower their respective 
enzyme activities and elevate acetaldehyde levels after the administration of ethanol. In the in 
vivo studies, the elevated acetaldehyde levels resulted in an aversion to ethanol intake as shown 
by a reduction in alcohol consumption.  
DISCUSSION 
Several studies found that individuals who possess functional polymorphic alleles of the 




al., 1999; Higuchi et al., 1995; Ocaranza et al., 2008). In fact, individuals who are heterozygous 
ALDH2*2/ALDH2*1 carriers were protected against alcohol abuse and alcoholism by around 66 
to 75% while homozygous ALDH2*2/ALDH2*2 carriers were nearly 100% protected (Chen et 
al., 1999; Ocaranza et al., 2008). ALDH2*2/*1 heterozygosity was found to display partial 
protection against alcoholism due to the presence of ALDH2*2 while individuals who were 
ALDH2*2/*1 heterozygous inactive and ADH2*1/*1 homozygous active still had a significantly 
high risk of alcoholism (Chen et al., 1999; Higuchi et al., 1995). However, individuals who were 
ALDH2*2/*1 heterozygous inactive and ADH2*2/*2 homozygous inactive were largely 
protected against risk of alcoholism. 
In the study done by Ocaranza and colleagues (2008), liver ALDH2 activity was reduced 
via a single administration of the AdV carrying an anti-ALDH2 antisense gene; the therapeutic 
AdV was also able to reduce alcohol intake for 34 days in rats, which was the longest period 
studied up until that point. This study along with the studies done Karahanian et al. (2005) and 
Garver et al. (2001) reveal that gene therapy that mimics the polymorphic nature of ALDH can 
be used as a possible long-term treatment option for alcohol-dependent animals. Furthermore, 
these studies showed that deterrence can be elicited after high alcohol drinking has been 
established, elevating the ability of gene therapy to be used as a possible treatment option for 
humans with alcoholism. According to Karahanian et al. (2005), therapeutic reduction of 
ALDH2 activity in the liver should be the primary aim in order to allow other tissues within the 
lungs, upper respiratory tract, and upper gastrointestinal tract to retain their ability to metabolize 
acetaldehyde. In doing so, risk of alcoholism in addition to risk of developing 
oropharyngolaryngeal, esophageal, and lung cancer due to the carcinogenic effects of 




The two studies done by Rivera-Meza et al. (2010 & 2012) incorporated gene therapy 
focused on ADH involvement in alcohol metabolism. In doing so, they found that ADH 
polymorphisms play a large contributing factor in ethanol aversion due to a burst in acetaldehyde 
production. Additionally, Rivera-Meza et al. (2012) found that simultaneously increasing ADH 
activity and reducing ALDH2 activity was able to reduce the voluntary ethanol intake in rodents, 
which provides evidence of new therapeutic strategies for the treatment of alcoholism. 
In order to bridge the gap between gene therapy used in animal studies and any potential 
future studies involving human subjects, more studies that consider the relationship between 
functional genetic polymorphisms and their interactions with developmental stages and 
variations in environmental context need to be pursued so that our understanding of how 
polymorphisms such as ADH and ALDH work to protect humans against alcoholism throughout 
their lifespan can be improved. Likewise, a greater number of animal studies that include larger 
sample populations need to be tested before implementing similar gene therapy techniques in 
humans to decrease the risk of alcoholism to ensure that methods are safe and that results are 
able to be reproduced and to the same magnitude.  
Future animal studies should test the effect of gene therapies similar to the ones described 
within the studies included in this systematic review with the addition of longer periods of 
abstinence during the withdrawal phase to more closely mimic the behavior of recovering 
alcoholics. To test this, helper-dependent AdVs (HD-AdV) that are able to express therapeutic 
genes for up to two years without the use of endogenous viral genes can potentially be used in 
future rat and nonhuman primate studies (Rivera-Meza et al., 2012). The large cloning capacity 
and ability to accommodate multiple transgenes and lower chronic toxicity of helper-dependent 




Furthermore, due to the intrinsic hepatotoxic effects of ethanol and the prolonged exposure to 
ethanol within the gene therapy studies discussed in this systematic review, future studies should 
be aware of and examine increases of acute and chronic hepatotoxicity of adenoviral vector 
administration in animals. 
Future studies involving human subjects should focus on the gene-environment 
interaction of ADH/ALDH and sociocultural factors/developmental stages. Likewise, important 
sociocultural variables such as mental health, personality traits, and relationships with parents 
need to be considered. These variables require that future studies utilize a longitudinal design so 
that fluctuations in the aforementioned variables are able to be observed and assessed effectively. 
Future studies should also strive to include other ethnicities (Middle East Asians, Caucasians, 
African Americans, etc.) when examining the gene-environment interaction seeing that familial, 
cultural, and peer interactions play a significant role in determining the protective effects of 
genes on alcoholism. These problems may be addressed within longitudinal studies that focus on 
alcohol behaviors and thought processes within a variety of ethnically different communities. As 
suggested by Irons, Iacono, Oetting, and Mcgue (2012), future studies should also examine 
measures such as levels of access to alcohol with the house, family/peer alcohol use, and overall 
beliefs on alcohol. Examining the gene-environment interaction is critical to any future 
understanding of how to better our currently existing treatments for alcoholism in both young 
adolescents and adults, and it is a necessary component to consider when bridging the gap 
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